Patents by Inventor Michel F. Lévesque

Michel F. Lévesque has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7041507
    Abstract: Disclosed is an in vitro method of transdifferentiating an epidermal basal cell into a cell having one or more morphological, physiological and/or immunological features of a glial cell. Also disclosed are such transdifferentiated cells and cell cultures derived from them. A kit for converting, in vitro, epidermal basal cells into cells having one or more morphological, physiological and/or immunological features of a glial cell is also disclosed.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: May 9, 2006
    Assignee: Cedars-Sinai Medical Center
    Inventors: Michel F. Levesque, Toomas Neuman
  • Patent number: 6949380
    Abstract: Disclosed is a method of transdifferentiating an epidermal basal cell into a cell having one or more morphological, physiological and/or immunological features of a neural progenitor, neuronal, or glial cell by culturing a proliferating epidermal basal cell population derived from the skin of a mammalian subject; exposing the epidermal basal cell(s) to an antagonist of bone morphogenetic protein (BMP), such as fetuin, noggin, chordin, gremlin, or follistatin; and growing the cell(s) in the presence of at least one antisense oligonucleotide comprising a segment of a human MSX1 gene and/or a segment of a human HES1 gene, or homologous non-human counterpart of either of these. Also disclosed is a transdifferentiated cell of epidermal origin and cell cultures derived therefrom.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: September 27, 2005
    Assignee: Cedars-Sinai Medical Center
    Inventors: Michel F. Lévesque, Toomas Neuman
  • Patent number: 6395546
    Abstract: The present invention relates to methods for generating dopaminergic neurons in vitro from embryonic and adult central nervous system cells. Specifically, these cells are isolated, cultured in vitro and stimulated to differentiate into dopaminergic neurons by down-regulating COUP-TFI and/or COUP-TFII expression or increasing NOT1 expression. These newly generated dopaminergic neurons may serve as an excellent source for cell replacement therapy in neurological disorders in which the dopaminergic system is compromised.
    Type: Grant
    Filed: February 1, 2000
    Date of Patent: May 28, 2002
    Assignee: NeuroGeneration, Inc.
    Inventors: Rita Zobel, Michel F. Levesque
  • Patent number: 6087168
    Abstract: The present invention is directed to method of converting, or transdifferentiating the epidermal cells into viable neurons useful in both cell therapy and gene therapy treatment methodologies. The method of transdifferentiating epidermal cells into neuronal cells comprises the following steps: obtaining skin cells from a patient; dedifferentiating these cells with an appropriate medium, neurotrophin or cytokine; transfecting the skin cells with one or more expression vector(s) encoding at least one neurogenic transcription factor or active fragments thereof; expressing at least one of the neurogenic transcription factors; growing the transfected cells in an appropriate medium; and adding to the medium one or more antisense oligonucleotide(s) corresponding to at least one negative regulator of neuronal differentiation, whereby the epidermal cells are transdifferentiated into neuronal cells.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: July 11, 2000
    Assignee: Cedars Sinai Medical Center
    Inventors: Michel F. Levesque, Toomas Neuman